Literature DB >> 24269585

Tissue-type plasminogen activator is not necessary for platelet-derived growth factor-c activation.

Kimberly J Riehle1, Melissa M Johnson2, Fredrik Johansson2, Renay L Bauer2, Brian J Hayes2, Debra G Gilbertson3, Aaron C Haran3, Nelson Fausto2, Jean S Campbell4.   

Abstract

Platelet-derived growth factors (PDGFs) are critical for development; their over-expression is associated with fibrogenesis. Full-length PDGF-C is secreted as an inactive dimer, requiring cleavage to allow receptor binding. Previous studies indicate that tissue-type plasminogen activator (tPA) is the specific protease that performs this cleavage; in vivo confirmation is lacking. We demonstrate that primary hepatocytes from tpa KO mice produce less cleaved active PDGF-CC than do wild type hepatocytes, suggesting that tPA is critical for in vitro activation of this growth factor. We developed mice that over-express full-length human PDGF-C in the liver; these mice develop progressive liver fibrosis. To test whether tPA is important for cleavage and activation of PDGF-C in vivo, we intercrossed PDGF-C transgenic (Tg) and tpa knock-out (KO) mice, anticipating that lack of tPA would result in decreased fibrosis due to lack of hPDGF-C cleavage. To measure levels of cleaved, dimerized PDGF-CC in sera, we developed an ELISA that specifically detects cleaved PDGF-CC. We report that the absence of tpa does not affect the phenotype of `PDGF-C Tg mice. PDGF-C Tg mice lacking tPA have high serum levels of cleaved growth factor, significant liver fibrosis, and gene expression alterations similar to those of PDGF-C Tg mice with intact tPA. Furthermore, urokinase plasminogen activator and plasminogen activator inhibitor-1 expression are increased in PDGF-C Tg; tpa KO mice. Our ELISA data suggest a difference between in vitro and in vivo activation of this growth factor, and our mouse model confirms that multiple proteases cleave and activate PDGF-C in vivo.
Copyright © 2013 The Authors. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  BrdU; CUB; ECM; H&E; HCC; IP; KO; Liver fibrosis; NPC; PAI-1; PDGF; Plasminogen activator; Platelet-derived growth factor; Tg; bromodeoxyuridine; complement subcomponents Clr/Cls, Uegf, Bmp1; extracellular matrix; hematoxylin & eosin; hepatocellular carcinoma; intraperitoneally; knock-out; non-parenchymal cell; plasminogen activator inhibitor-1; platelet-derived growth factor; tPA; tissue-type plasminogen activator; transgenic; uPA; urokinase plasminogen activator

Mesh:

Substances:

Year:  2013        PMID: 24269585      PMCID: PMC3932705          DOI: 10.1016/j.bbadis.2013.11.013

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  31 in total

Review 1.  The PDGF family: four gene products form five dimeric isoforms.

Authors:  Linda Fredriksson; Hong Li; Ulf Eriksson
Journal:  Cytokine Growth Factor Rev       Date:  2004-08       Impact factor: 7.638

2.  Soluble urokinase plasminogen activator receptor is compartmentally regulated in decompensated cirrhosis and indicates immune activation and short-term mortality.

Authors:  H W Zimmermann; P A Reuken; A Koch; M Bartneck; D H Adams; C Trautwein; A Stallmach; F Tacke; T Bruns
Journal:  J Intern Med       Date:  2013-03-17       Impact factor: 8.989

3.  Plasminogen activators direct reorganization of the liver lobule after acute injury.

Authors:  J A Bezerra; A R Currier; H Melin-Aldana; G Sabla; T H Bugge; K W Kombrinck; J L Degen
Journal:  Am J Pathol       Date:  2001-03       Impact factor: 4.307

4.  PDGF-C is a new protease-activated ligand for the PDGF alpha-receptor.

Authors:  X Li; A Pontén; K Aase; L Karlsson; A Abramsson; M Uutela; G Bäckström; M Hellström; H Boström; H Li; P Soriano; C Betsholtz; C H Heldin; K Alitalo; A Ostman; U Eriksson
Journal:  Nat Cell Biol       Date:  2000-05       Impact factor: 28.824

5.  Platelet-derived growth factor C (PDGF-C), a novel growth factor that binds to PDGF alpha and beta receptor.

Authors:  D G Gilbertson; M E Duff; J W West; J D Kelly; P O Sheppard; P D Hofstrand; Z Gao; K Shoemaker; T R Bukowski; M Moore; A L Feldhaus; J M Humes; T E Palmer; C E Hart
Journal:  J Biol Chem       Date:  2001-04-10       Impact factor: 5.157

6.  Enhanced plasminogen activator inhibitor-1 expression in transgenic mice with hepatocyte-specific overexpression of superoxide dismutase or glutathione peroxidase.

Authors:  Kai Franke; Katja Curth; Jacek Lenart; Doreen Knochenhauer; Thomas Kietzmann
Journal:  Antioxid Redox Signal       Date:  2004-08       Impact factor: 8.401

7.  Tissue plasminogen activator is a potent activator of PDGF-CC.

Authors:  Linda Fredriksson; Hong Li; Christina Fieber; Xuri Li; Ulf Eriksson
Journal:  EMBO J       Date:  2004-09-16       Impact factor: 11.598

8.  Treatment of colorectal and hepatocellular carcinomas by adenoviral mediated gene transfer of endostatin and angiostatin-like molecule in mice.

Authors:  V Schmitz; L Wang; M Barajas; C Gomar; J Prieto; C Qian
Journal:  Gut       Date:  2004-04       Impact factor: 23.059

9.  Adenoviral vector-mediated augmentation of epidermal growth factor receptor (EGFr) enhances the radiosensitization properties of anti-EGFr treatment in prostate cancer cells.

Authors:  James A Bonner; Donald J Buchsbaum; Buck E Rogers; William E Grizzle; Hoa Q Trummell; David T Curiel; John B Fiveash; Roger Ove; Kevin P Raisch
Journal:  Int J Radiat Oncol Biol Phys       Date:  2004-03-01       Impact factor: 7.038

10.  Exogenous PDGF-D is a potent mesangial cell mitogen and causes a severe mesangial proliferative glomerulopathy.

Authors:  Kelly L Hudkins; Debra G Gilbertson; Matthew Carling; Sekiko Taneda; Steven D Hughes; Matthew S Holdren; Thomas E Palmer; Stavros Topouzis; Aaron C Haran; Andrew L Feldhaus; Charles E Alpers
Journal:  J Am Soc Nephrol       Date:  2004-02       Impact factor: 10.121

View more
  4 in total

Review 1.  Pharmacological targeting of the PDGF-CC signaling pathway for blood-brain barrier restoration in neurological disorders.

Authors:  Sebastian A Lewandowski; Linda Fredriksson; Daniel A Lawrence; Ulf Eriksson
Journal:  Pharmacol Ther       Date:  2016-08-12       Impact factor: 12.310

Review 2.  Plasmin-dependent modulation of the blood-brain barrier: a major consideration during tPA-induced thrombolysis?

Authors:  Be'eri Niego; Robert L Medcalf
Journal:  J Cereb Blood Flow Metab       Date:  2014-06-04       Impact factor: 6.200

3.  Role of Smad3 in platelet-derived growth factor-C-induced liver fibrosis.

Authors:  Jung Il Lee; Jocelyn H Wright; Melissa M Johnson; Renay L Bauer; Kristina Sorg; Sebastian Yuen; Brian J Hayes; Lananh Nguyen; Kimberly J Riehle; Jean S Campbell
Journal:  Am J Physiol Cell Physiol       Date:  2015-12-02       Impact factor: 4.249

4.  An ATF6-tPA pathway in hepatocytes contributes to systemic fibrinolysis and is repressed by DACH1.

Authors:  Ze Zheng; Lalitha Nayak; Wei Wang; Arif Yurdagul; Xiaobo Wang; Bishuang Cai; Stephanie Lapping; Lale Ozcan; Rajasekhar Ramakrishnan; Richard G Pestell; Mukesh K Jain; Ira Tabas
Journal:  Blood       Date:  2018-12-01       Impact factor: 25.476

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.